InVivo Therapeutics

$0.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.1542 (-14.55%) Today
-$0.0058 (-0.64%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell NVIV and other stocks, options, and ETFs commission-free!

About NVIV

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA. The listed name for NVIV is InVivo Therapeutics Holdings Corp Common Stock.

CEO
Richard Toselli
Employees
6
Headquarters
Cambridge, Massachusetts
Founded
2005
Market Cap
19.52M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.76M
High Today
$1.03
Low Today
$0.84
Open Price
$1.00
Volume
3.37M
52 Week High
$5.80
52 Week Low
$0.4975

NVIV Earnings

-$0.49
-$0.33
-$0.16
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 16, Pre-Market

You May Also Like

IFJPY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure